Allergan, Inc.

NYSE: AGN
The top analyst upgrades, downgrades and other research calls from Friday include Albermarle, Allergan, Boston Scientific, eBay, FedEx, Gogo, LendingTree, Nokia, UPS and Vertex Pharmaceuticals.
A new Merrill Lynch research report includes a high-profile financial addition to the firm's US 1 portfolio of high-conviction stock picks.
Though Allergan reported better than expected quarterly results before the markets opened on Tuesday, its shares retreated.
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Botox maker Allergan said Wednesday that it is firing 1,000 employees and eliminating about 400 unfilled job openings as it tries to make good on a promise to cut up to $400 million in costs in 2018.
Paratek Pharmaceuticals saw its shares make a handy gain on Thursday after the firm announced that the FDA accepted its New Drug Application for the review of Seysara for the treatment of moderate to...
The top analyst upgrades, downgrades and other research calls from Thursday include Amazon, Allergan, Borg Warner, Lam Research, Mellanox Technologies and Shake Shack.
Allergan, Cemex, Delphi Technologies, and Eldorado Gold all posted new 52-week lows on Tuesday.
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
The top analyst upgrades, downgrades and other research calls from Wednesday include Allergan, Autodesk, Home Depot, Marvell, Qualcomm, UnitedHealth and Walmart.
Why Wall Street “Super Investors” are buying Facebook, AliBaba, Allergan, Capital One Financial, and Micron Technology.
Allergan, Immune Pharmaceuticals, Newell Brands, and Sally Beauty all posted new 52-week lows on Thursday.
The top analyst upgrades, downgrades and other research calls from Thursday include Adobe, Allergan, American Express, Baker Hughes, Nike, Northern Dynasty Minerals, Sprint and Wayfair.
Wednesday was a positive day for the U.S. broad markets and again all exchanges hit new all-time highs. The Dow performed especially well breaking and holding above 23,000. Crude oil posted another...
U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of the market has not come without controversy in the past year and a half.